Publication | Closed Access

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

Breast OncologyPredictive MarkersTopo-isomerase IiαMedicinePathologyBreast CancerAdjuvant CmfCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer